Dogwood Therapeutics, Inc.
DWTX - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$43.51M
Close$
$0.77
36.6% downside
Current Fair Value
36.6% downsideOvervalued by 36.6% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $43.51 Million |
|---|---|
| Enterprise Value | $34.04 Million |
| Earnings per Share | $-4.32 |
| Beta | 1.94 |
| Outstanding Shares | 34,129,553 |
Return
| Return on Equity | 23311.17% |
|---|---|
| Return on Assets | 19798.55% |
| Return on Invested Capital | -20292.25% |
Valuation & Multiples
| P/E Ratio | -0.14 |
|---|---|
| PEG | 0.14 |
| Price to Sales | - |
| Price to Book Ratio | 0.61 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-0.14
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.15
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.00%▼ 11.22% |
|---|---|
| Total Invested | $1,029▼ 99.98% |
| Investors Holding | 1▼ 15.00% |
About Dogwood Therapeutics, Inc.
12 employees
CEO: Gregory Duncan
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate...